Shire plc
 |
|
| Type | Public (LSE: SHP) (NASDAQ: SHPGY) (TSX:SHPGY-Q) |
|---|---|
| Founded | 1986 |
| Headquarters | Basingstoke, England, UK |
| Key people | James Cavanaugh, Chairman Angus Russell, CEO |
| Industry | Pharmaceuticals |
| Revenue | $2,436 million (2007) |
| Operating income | $(1,379) million (2007) |
| Net income | $(1,451) million (2007) |
| Website | www.shire.com |
Shire plc (LSE: SHP), (NASDAQ: SHPGY), (TSX:SHPGY-Q) is a British manufacturer of pharmaceuticals including Adderall XR, Carbatrol, Fosrenol, and the recently released Vyvanse.
|
|
Shire was founded by Harry Stratford and James Murray in 1986.[1] It was first listed on the London Stock Exchange in 1996[1] and in 1997 it went on to acquire Parmavene and Richmond Pharmaceutical Company.[1] In 2007 it acquired New River Pharmaceuticals Inc, a leading US drug maker, for $2.3bn.[2]
The Company seeks to develop and market products within advanced biotechnology for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.
The Company focuses its drug research and development on the relatively common mental abnormality Attention Deficit Hyperactivity Disorder (ADHD), as is made evident by the fact that three of its currently leading medications (Adderall/Adderall XR, Daytrana, and the newly developed Vyvanse), are intended for that disorder. However the Company also works on gastrointestinal (GI) treatments, human genetic therapies (HGT) and renal diseases.
Key products are as follows:[3]
- Adderall XR: All age Attention Deficit Hyperactivity Disorder
- Daytrana: Pediatric Attention Deficit Hyperactivity Disorder
- Vyvanse: All age Attention Deficit Hyperactivity Disorder
- Elaprase: Hunter Syndrome
- Replagal: Fabry's disease
- Fosrenol: Hyperphosphatemia associated with End-Stage Renal Disease
- Dynepo: Anemia associated with End-Stage Renal Disease
- Carbatrol: Epilepsy
- Reminyl (also sold as Razadyne): Alzheimer's Disease
- Xagrid (sold as Agrylin in the U.S.): Essential Thrombocytosis
The corporate offices are located in Basingstoke, Hampshire, UK. Other major offices are located in the United States in Wayne, Pennsylvania and Cambridge, Massachusetts. In addition, Shire owns a manufacturing site in Owings Mills, Maryland. The company has recently announced that it will move its tax domicile to Ireland.[4] The move will be effected through the creation of a new holding company in Jersey, which will pay reduced tax on global earnings in Ireland. The new structure is thought to be motivated mainly by the rule that royalties on patents lodged in Ireland are tax free.
The non-executive Board Chairman is Dr. James Cavanaugh. Matthew Emmens is the Chief Executive Officer and Chairman of the Executive Committee. The President of the Human Genetic Therapies division is Sylvie Gregoire and Mike Cola is the President of Specialty Pharmaceuticals.
